AEterna Zentaris News

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, is pleased to announce the appointment of Pierre Lapalme to its Board of Directors.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia , with cetrorelix pamoate.

Aeterna Zentaris Inc. shares plunged Monday after the Quebec-based company announced that a European drug trial had failed to provide clear evidence that one of its drug candidates is an effective treatment for enlarged prostate glands.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc.

AEterna Zentaris' Anti-Cancer Compound, Perifosine , Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma QUEBEC CITY , Dec.

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on AEterna Zentaris Inc., . Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 , in patients with advanced or recurrent endometrial cancer.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine at 51st Annual Meeting of the American Society of Hematology Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

QUEBEC CITY, Oct. 23 e-Aeterna-Z-Financing QUEBEC CITY , Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia , met its primary endpoint.

Aeterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the ...

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Shares in pharmaceutical company Aeterna Zentaris Inc. tumbled nearly 60 per cent Monday after studies questioned the benefit of its prostate treatment drug cetrorelix pamoate.

Shares of Aeterna Zentaris dropped almost 70 percent on Monday after it said late-stage results for its treatment for enlarged prostates missed some key goals, raising doubts that the treatment will get regulatory approval.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia , with its lead endocrinology compound for urology, cetrorelix pamoate.